Compounds and Compositions as Modulators of TLR Signaling
Summary
The European Patent Office published Patent EP4217342A1 granting Neuropore Therapies, Inc. exclusive rights to novel TLR signaling modulator compounds and compositions. The patent covers small molecule modulators with potential therapeutic applications for neurological conditions including Alzheimer's disease. Protection extends across 28 designated European contracting states including Germany, France, the United Kingdom, Italy, Spain, and the Netherlands.
What changed
The European Patent Office published patent application EP4217342A1 for Neuropore Therapies, Inc., covering novel compounds and compositions that modulate TLR (Toll-like receptor) signaling pathways. The patent application includes 15 distinct IPC classifications spanning heterocyclic organic chemistry compounds (C07D series) with specific therapeutic applications indicated for neurological conditions (A61P 25/28), suggesting applications in Alzheimer's disease and related neurodegenerative disorders.
For pharmaceutical manufacturers and biotech companies developing TLR-targeted therapeutics, this patent establishes intellectual property barriers in the European market. Competitors pursuing similar TLR modulator programs must consider this patent when assessing freedom-to-operate for European commercialization. The designated states include all major European pharmaceutical markets, requiring careful evaluation of potential licensing or design-around strategies.
What to do next
- Review patent claims for freedom-to-operate implications
- Assess licensing opportunities for TLR modulator technology
- Monitor for related patent family filings in other jurisdictions
Archived snapshot
Apr 8, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR SIGNALING
Publication EP4217342A1 Kind: A1 Apr 01, 2026
Applicants
Neuropore Therapies, Inc.
Inventors
NATALA, Srinivasa Reddy, WRASIDLO, Wolfgang J., STOCKING, Emily M.
IPC Classifications
C07D 205/04 20060101AFI20260224BHEP C07D 207/09 20060101ALI20260224BHEP C07D 207/27 20060101ALI20260224BHEP C07D 211/26 20060101ALI20260224BHEP C07C 235/54 20060101ALI20260224BHEP A61P 25/28 20060101ALI20260224BHEP C07D 211/38 20060101ALI20260224BHEP C07D 211/54 20060101ALI20260224BHEP C07D 213/74 20060101ALI20260224BHEP C07D 213/75 20060101ALI20260224BHEP C07D 213/85 20060101ALI20260224BHEP C07D 221/20 20060101ALI20260224BHEP C07D 231/12 20060101ALI20260224BHEP C07D 233/32 20060101ALI20260224BHEP C07D 233/70 20060101ALI20260224BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Related changes
Get daily alerts for ChangeBridge: EPO Bulletin - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ChangeBridge: EPO Bulletin - Organic Chemistry (C07D) publishes new changes.